Cogent Biosciences Inc [COGT] stock is trading at $16.27, up 0.49%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The COGT shares have gain 3.24% over the last week, with a monthly amount glided 27.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cogent Biosciences Inc [NASDAQ: COGT] stock has seen the most recent analyst activity on September 03, 2025, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $30. Previously, Scotiabank started tracking the stock with Sector Outperform rating on March 07, 2025, and set its price target to $17. On December 11, 2024, downgrade downgraded it’s rating to Hold. Robert W. Baird downgraded its rating to a Neutral and decreased its price target to $8 on February 26, 2024. Citigroup initiated its recommendation with a Buy and recommended $11 as its price target on February 08, 2024. Wedbush downgraded its rating to Neutral for this stock on December 11, 2023, but kept the price target unchanged to $5. In a note dated December 08, 2023, JP Morgan initiated an Overweight rating and provided a target price of $18 on this stock.
Cogent Biosciences Inc [COGT] stock has fluctuated between $3.72 and $16.46 over the past year. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. Cogent Biosciences Inc [NASDAQ: COGT] shares were valued at $16.27 at the most recent close of the market. An investor can expect a potential return of 53.66% based on the average COGT price forecast.
Analyzing the COGT fundamentals
Gross Profit Margin for this corporation currently stands at -0.29% with Operating Profit Margin at -69.82%, Pretax Profit Margin comes in at -66.19%, and Net Profit Margin reading is -66.19%. To continue investigating profitability, this company’s Return on Assets is posted at -1.03, Equity is -1.2 and Total Capital is -1.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Cogent Biosciences Inc’s Current Ratio is 4.19. As well, the Quick Ratio is 4.19, while the Cash Ratio is 2.18.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Jul 10 ’25 when 2.78 million shares were purchased. Chief Commercial Officer, Pinnow Cole completed a deal on Jan 14 ’25 to buy 43750.0 shares.
